Botulinum Toxin in Headache Management

Botulinum Toxin: Therapeutic Clinical Practice and Science

Volumn , Issue , 2009, Pages 214-222

  Silberstein, Stephen D ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b JEFFERSON HEADACHE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77950989603     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-4928-9.00017-2     Document Type: Chapter

References (43)

1. Headache: Hope Through Research 2002, 2-158. National Institute of Neurological Disorders and Stroke (NINDS), US Department of Health and Human Services, National Institutes of Health. NIH publication, Bethesda, MD.
2. Classification and diagnostic criteria for headache disorders, cranial neuralgia, and facial pain. Cephalalgia 1988, 8(suppl 7):1-96. Headache Classification Committee of the International Headache Society.
3. Headache Classification Committee. The International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004;24(suppl 1):1-160.
4. Critchley M Migraine: from Cappadocia to Queen Square 1967, Heinemann, London, UK.
5. Silberstein SD, Saper JR, Freitag F Migraine: Diagnosis and treatment. Wolff's Headache and Other Head Pain 2001, 121-237. Oxford University Press, New York. 7th. S.D. Silberstein, R.B. Lipton, D.J. Dalessio (Eds.).
6. Stewart WF, Shechter A, Rasmussen RK Migraine prevalence. A review of population-based studies. Neurology 1994, 44:S17-S23.
7. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001, 41:646-657.
8. Lipton RB, Hamelsky SW, Stewart WF Epidemiology and impact of headache. Wolff's Headache and Other Head Pain 2001, 85-107. Oxford University Press, New York, . 7th. S.D. Silberstein, R.B. Lipton, D.J. Dalessio (Eds.).
9. Stewart WF, Lipton RB, Celentano DD, Reed ML Prevalence of migraine headache in the United States. Relation to age, income, race and other sociodemographic factors. JAMA 1992, 267:64-69.
10. World Health Organization. Headache disorders. Fact sheet No 277. Available at: 2007 . http://www.who.int/mediacentre/factsheets/fs277/en/print.html.
11. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML Burden of migraine in the United States: disability and economic costs. Arch Intern Med 1999, 159:813-818.
12. Silberstein SD, Stark SR, Lucas SM, Christie SN, DeGryse RE, Turkel CC Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2005, 80:1126-1137.
13. Scher AI, Stewart WF, Liberman J, Lipton RB Prevalence of frequent headache in a population sample. Headache 1998, 38:497-506.
14. Castillo J, Munoz P, Guitera V, Pascual J Epidemiology of chronic daily headache in the general population. Headache 1999, 39:190-196.
15. Wang SJ, Fuh JL, Lu SR, Liu CY, Hsu LC, Wang PN, et al. Chronic daily headache in Chinese elderly: prevalence, risk factors and biannual follow-up. Neurology 2000, 54:314-319.
16. Bigal ME, Rapoport AM, Lipton RB, Tepper SJ, Sheftell FD Assessment of migraine disability using the Migraine Disabiilty Assessment (MIDAS) Questionnaire: a comparison of chronic migraine with episodic migraine. Headache 2003, 43:336-342.
17. Meletiche DM, Lofland JH, Young WB Quality of life differences between patients with episodic and transformed migraine. Headache 2001, 41:573-578.
18. Schwartz BS, Stewart WF, Simon D, Lipton RB Epidemiology of tension-type headache. JAMA 1998, 279:381-383.
19. Silberstein SD Migraine. Lancet 2004, 363:381-391.
20. Goadsby PJ Pathophysiology of headache. Wolff 2001, 57-72. Oxford University Press, New York. 7. S.D. Silberstein, R.B. Lipton, D.J. Dalessio (Eds.).
21. Silberstein SD, Gobel H, Jensen R, Elkind AH, deGryse R, Walcott JM, et al. Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study. Cephalalgia 2006, 26:790-800.
22. Blumenfeld AM, Binder W, Silbrestein SD, Blizter A Procedures for administering botulinum toxin type A for migraine and tension-type headache. Headache 2003, 43:884-891.
23. Aoki KR, Guyer B Botulinum toxin type A and other botulinum toxin serotypes; a comparative review of biochemical and pharmacological actions. Eur J Neurol 2001, 8(suppl 5):21-29.
24. Mauskop A The use of botulinum toxin in the treatment of headaches. Pain Physician 2004, 7:377-387.
25. BOTOX® package insert. Irvine, CA: Allergan, Inc. 2004.
26. Binder WJ, Brin MF, Blitzer A, Shoenrock LD, Pogoda JM Botulinum toxin type A (Botox) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg 2000, 123:669-676.
27. Jensen R, Bendtsen L, Olesen J Muscular factors are of importance in tension-type headache. Headache 1998, 38:10-17.
28. Jakubowski M, Silberstein S, Ashkenazi A, Burstein R Can allodynic migraine patients be identified interictally using a questionnaire?. Neurology 2005, 65:1419-1422.
29. Jakubowski M, McAllister PJ, Bajwa ZH, Ward TN, Smith P, Burstein R Exploding vs. imploding headache in migraine prophylaxis with Botulinum Toxin A. Pain 2006, 125:286-295.
30. Dodick DW, Mauskop A, Elkind AH, deGryse R, Brin MF, Silberstein SD Botulinum toxin type A for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 2005, 45:315-324.
31. Aoki KR Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003, 43(suppl 3):S109-S115.
32. Cui M, Khanijou S, Rubino J, Aoki KR Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004, 107:125-133.
33. Oshinsky ML Botulinum toxins and migraine: how does it work. Practical Neurol 2004, (Suppl):10-13.
34. Oshinsky M, Poso-Rosich P, Luo J, Hyman S, Silberstein SD Botulinum toxin A blocks sensitization of neurons in the trigeminal nucleus caudalis [abstract]. Cephalalgia 2004, 24:781.
35. Schulte-Mattler WJ, Leinisch E Evidence based medicine on the use of botulinum toxin for headache disorders. J Neural Transm 2008, 115:647-651.
36. Silberstein SD, Mathew N, Saper J, Jenkin S Botulinum toxin type A as a migraine preventive treatment: for the Botox® Migraine Clinical Research Group. Headache 2000, 40:445-450.
37. Evers S, Vollmer-Haase J, Schwaag S, Rahmann A, Husstedt IW, Frese A Botulinum toxin A in the prophylactic treatment of migraine - a randomized, double-blind, placebo-controlled study. Cephalalgia 2004, 24:838-843.
38. Saper JR, Mathew NT, Loder EW, deGryse R, VanDenburgh AM A double-blind, randomized, placebo-controlled comparison of botulinum toxin type A injection sites and doses in the prevention of episodic migraine. Pain Med 2007, 8:478-485.
39. Elkind AH, O'Carroll P, Blumenfeld A, deGryse R, Dimitrova R A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis. J Pain 2006, 7:688-696.
40. Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 2005, 45:293-307.
41. Mathew NT, Kaup AO The use of botulinum toxin type A in headache treatment. Curr Treat Options Neurol 2002, 4:365-373.
42. Rozen D, Sharma J Treatment of tension-type headache with botox: a review of the literature. Mt Sinai J Med 2006, 73:493-4988.
43. Brin MF, Swope DM, O'Brien C, Abbasi S, Pogoda JM Botox for migraine: double-blind, placebo-controlled, region-specific evaluation [abstract]. Cephalalgia 2000, 20:421-422.